Search research articles
Contact Us
Filters
Showing results (71-80 of 118) with videos related to
Page
of 12
Sort By:
Oncotarget
|
June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
Lan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.
Clinical Lung Cancer
|
December 25, 2024
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease
Chang Lu, Hong-Hong Yan, Chan-Yuan Zhang, et al.
Clinical Lung Cancer
|
October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC
Yuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
Si-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.
Nature Communications
|
January 13, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
Anna Li, Wei-Neng Feng, Juan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer
Qing Zhou, Xu-Chao Zhang, Zhi-Hong Chen, et al.
Thoracic Cancer
|
April 19, 2022
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer
Kai-Cheng Peng, Jun-Wei Su, Zhi Xie, et al.
Experimental Hematology & Oncology
|
November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Lun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Eclinicalmedicine
|
June 8, 2026
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China
Chao Zhang, Ben-Yuan Jiang, Li-Xu Yan, et al.
JTO Clinical and Research Reports
|
September 16, 2024
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma
Jia-Xin Lin, Kai Yin, Li-Xu Yan, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 118) with videos related to
Sort By:
Page
of 12
Oncotarget
|
June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
Lan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.
Clinical Lung Cancer
|
December 25, 2024
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease
Chang Lu, Hong-Hong Yan, Chan-Yuan Zhang, et al.
Clinical Lung Cancer
|
October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC
Yuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
Si-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.
Nature Communications
|
January 13, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
Anna Li, Wei-Neng Feng, Juan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer
Qing Zhou, Xu-Chao Zhang, Zhi-Hong Chen, et al.
Thoracic Cancer
|
April 19, 2022
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer
Kai-Cheng Peng, Jun-Wei Su, Zhi Xie, et al.
Experimental Hematology & Oncology
|
November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Lun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Eclinicalmedicine
|
June 8, 2026
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China
Chao Zhang, Ben-Yuan Jiang, Li-Xu Yan, et al.
JTO Clinical and Research Reports
|
September 16, 2024
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma
Jia-Xin Lin, Kai Yin, Li-Xu Yan, et al.
Page
of 12